Clinical trials: Acquired Immune Deficiency Syndrome (AIDS)
Infection, Human Immunodeficiency Virus
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
ING116070 is a Phase IIIb single-arm, open-label, multicenter study. The study will be conducted in approximately 14 HIV-1 infected antiretroviral therapy (ART)-naïve subjects.
- Trial name
- NCT01499199
- Testing
- Dolutegravir
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- ViiV Healthcare
HIV/AIDS, Adherence
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
Development of Real-Time Antiretroviral Therapy Adherence Intervention in Uganda (The Wisepill Study).
- Trial name
- NCT01957865
- Testing
- Fixed SMS, real-time monitoring, Triggered SMS, real-time monitoring
- Where
- Uganda
- Volunteers
- 63 people
- Sponsor
- Massachusetts General Hospital
HIV (Human Immunodeficiency Virus), Sleep
Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV
In South Africa, antiretroviral therapy (ART) has transformed HIV into a chronic, manageable condition, with high rates of viral suppression.
- Trial name
- SOMNART (NCT07673965)
- Testing
- Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg, Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg
- Volunteers
- 40 people
- Sponsor
- University of Witwatersrand, South Africa
Infections, Human Immunodeficiency Virus and Herpesviridae
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus (HIV)-1 infection by GlaxoSmithKline (GSK) on behalf of Shionogi-ViiV HealthcareLLC.
- Trial name
- NCT01209065
- Testing
- GSK1349572, Fosamprenavir, Ritonavir
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects
To determine the safety and tolerance of daily oral hypericin when given to achieve target trough levels within defined cohorts. To determine the responses of surrogate markers of HIV infection to daily oral hypericin.
- Trial name
- NCT00000792
- Testing
- Hypericin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r
For participants with HIV taking either lopinavir or fosamprenavir who have elevated triglycerides, this trial will study the change in triglycerides after switching protease inhibitors.
- Trial name
- LARD (NCT00756730)
- Testing
- ATV/r, DRV/r
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Community Research Initiative of New England
HIV Infections
The Effect of Stomach Acid on Foscarnet
To see if ranitidine, by reducing stomach acidity, can enhance the effectiveness of foscarnet, by making foscarnet more available to the body. Foscarnet is an antiviral compound.
- Trial name
- NCT00000964
- Testing
- Ranitidine hydrochloride, Foscarnet sodium
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Toxoplasmosis, Cerebral, HIV Infections
Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.
- Trial name
- NCT00002064
- Testing
- Pyrimethamine, Clindamycin
- Where
- United States
- Sponsor
- Palo Alto Medical Foundation
HIV Infections, Acquired Immunodeficiency Syndrome
TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients
The purpose of this study is to determine the pharmacokinetics (how the body absorbs, distributes, metabolizes and eliminates a drug) (PK) of ETR when given with ATV/rtv and 1 NRTI in treatment experienced HIV-1 infected…
- Trial name
- NCT00896051
- Testing
- Atazanavir (ATV) 300 mg, Atazanavir (ATV) 400 mg, Ritonavir (rtv) 100 mg
- Where
- 18 sites in United States, Argentina and 3 more
- Volunteers
- 50 people
- Sponsor
- Janssen R&D Ireland
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Candidiasis, Oral, HIV Infections
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients…
- Trial name
- NCT00002431
- Testing
- Chlorhexidine gluconate
- Where
- 5 sites in United States
- Sponsor
- Procter and Gamble
HIV/AIDS
Changing Health Through Food Support (CHEFS) Program
UCSF and Project Open Hand (POH), a community based organization in San Francisco which provides meals and groceries to chronically ill clients in the Bay Area, have partnered to conduct an initial randomized controlled trial…
- Trial name
- CHEFS (NCT03191253)
- Testing
- Medically-appropriate meals and groceries
- Volunteers
- 191 people
- Sponsor
- University of California, San Francisco
Alcohol Dependence
Reducing Alcohol Dependence Among HIV-Positive Individuals
The purpose of this study is to compare the effects of interventions for drinking-reduction and antiretroviral therapy (ART) adherence among HIV-positive primary care patients.
- Trial name
- NCT02501057
- Testing
- Clinician's Guide, Enhanced Motivational Interviewing, Enhanced Clinician's Guide
- Volunteers
- 133 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Substance Dependence, HIV (Human Immunodeficiency Virus)
Pre-exposure Prophylaxis (PrEP) for Health
This randomized controlled trial will test the efficacy of "PrEP for Health," a behavioral intervention to improve the use of antiretroviral pre-exposure prophylaxis (PrEP) among at-risk people who inject drugs (PWID) in two…
- Trial name
- PrEP (NCT04430257)
- Testing
- HIV and PrEP education, Motivational interviewing, Problem-solving and planning
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Brown University
HIV Infections, AIDS
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression
Study Hypothesis Evaluation of the durability of the combination Tenofovir and Hydroxyurea to maintain viral suppression below 50 copies/ml in volunteers who have achieved viral suppression on a standard HAART regimen.
- Trial name
- HADIT (NCT00344981)
- Testing
- Tenofovir, Hydroxyurea
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Maryland, Baltimore
HIV Antiretroviral Therapy (ART) Adherence, Alcohol Consumption
Pilot of an Intervention to Reduce Alcohol Use and Improve ART Adherence Among Men Living With HIV With Pregnant Partners in Uganda.
Hazardous alcohol use, which is common among men in Uganda, is a primary driver of both HIV risk and intimate partner violence (IPV) in this setting.
- Trial name
- Kisoboka Amaka (NCT06900634)
- Testing
- Kisoboka Amaka, Screening and Referral
- Where
- Uganda
- Volunteers
- 60 people
- Sponsor
- San Diego State University
HIV/AIDS, HIV Infections
Using HIV Risk Assessment Tool to Promote HIV Testing Among Men Who Have Sex With Men
The objective of the study is to evaluate the effectiveness of a HIV risk assessment tool to promote HIV testing and to reduce high risk sexual behaviors among men who have sex with men (MSM).
- Conditions
- HIV/AIDS, HIV Infections, Social Media
- Trial name
- online-RASSL (NCT03320239)
- Testing
- HIV risk assessment and tailored suggestions, HIV risk behavior assessment
- Where
- China
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC
AIDS
Comparison of Facility and Home-based ART Delivery Systems in Uganda
The study is a 3-year, randomized trial to compare ART delivery through two different models: a) ART delivered through health facilities by clinically qualified staff and b) home-based care in which lay workers, i.e.
- Trial name
- NCT00144365
- Testing
- Antiretroviral therapy
- Where
- Uganda
- Volunteers
- 1,453 people
- Sponsor
- Centers for Disease Control and Prevention
Hypertriglyceridemia, HIV Infections
Effect of Soluble Fiber on Hypertriglyceridemia and Immune Profile in HIV-positive Individuals.
The purpose of this study was to assess the effect of soluble fiber® (partially hydrolyzed guar gum) supplementation on hypertriglyceridemia and immune profile in HIV-positive individuals on HAART.
- Trial name
- NCT00540111
- Testing
- soluble fiber® (partially hydrolyzed guar gum)
- Volunteers
- 19 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Sexually Transmitted Infection, HIV/AIDS
Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes (Philani Ndiphile)
This study aims to evaluate different screening strategies to decrease the burden of Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV) among pregnant women, and reduce adverse birth outcomes.
- Conditions
- Sexually Transmitted Infection, HIV/AIDS, Cost-effectiveness, Birth Outcomes
- Trial name
- NCT04446611
- Testing
- First antenatal care + test-of-cure, First antenatal care + week 30-34 gestation (no test-of-cure)
- Where
- South Africa
- Volunteers
- 2,247 people, healthy volunteers welcome
- Sponsor
- Foundation for Professional Development (Pty) Ltd